Marché du contrôle de la qualité des diagnostics in vitro (DIV) en Arabie saoudite, en Turquie et en Égypte – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché du contrôle de la qualité des diagnostics in vitro (DIV) en Arabie saoudite, en Turquie et en Égypte

La prévalence croissante des maladies chroniques en Arabie saoudite, en Turquie et en Égypte a accru la demande du marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur le lancement et l'approbation de divers produits au cours de cette période cruciale. En outre, l'augmentation des services de contrôle qualité améliorés contribue également à la demande croissante du marché du contrôle qualité des DIV.

Le marché du contrôle de la qualité des diagnostics in vitro (DIV) en Arabie saoudite, en Turquie et en Égypte devrait connaître une croissance du marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 4,8 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 1 260,66 milliers USD d'ici 2030 contre 867,09 milliers USD en 2022.

Définition du marché

Les produits de diagnostic in vitro sont des réactifs, instruments et systèmes destinés à être utilisés pour diagnostiquer une maladie ou d'autres conditions, y compris pour déterminer l'état de santé, afin de guérir, d'atténuer, de traiter ou de prévenir une maladie ou ses séquelles. Ces produits sont destinés à être utilisés pour la collecte, la préparation et l'examen d'échantillons prélevés sur le corps humain.

IVD quality controls are samples/materials used to validate the reliability of the IVD testing system to ensure the accuracy of test results and evaluate the impact of factors such as environmental conditions and operator’s performance on test results. Moreover, they can also be used to monitor a patient’s health, cure diseases, and also enable medical professionals to identify the most effective treatment procedure or therapy for the patient.

 In Vitro Diagnostics (IVD) Quality Control Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints and challenges. All of this is discussed in detail as below:

Drivers

• Rising Prevalence of Chronic Diseases Across Saudi Arabia, Turkey, and Egypt

Chronic diseases and conditions are on the rise globally. An aging population and a sedentary lifestyle are contributing to a steady increase in long-term health problems. An increasing prevalence of chronic and infectious diseases has led to the launch of rapid diagnostic and testing tools by leading market players. Besides, the rising adoption of self-test and point-of-care devices is further accelerating the growth of in-vitro diagnostics devices across the globe

Thus, the increasing number of chronic disease are expected to accelerate the growth of the IVD quality control market significantly in the nearby future.

• Rising Adoption of Quality Control Solutions in Laboratories and Hospitals

Laboratory testing of patient samples can be a complex procedure, depending on clinical analysis, microbiological study, or blood banking testing among other facets of the clinical laboratory. Quality control (QC) is one of the most important impacts on laboratory testing-it ensures both the precision and accuracy of patient sample results. The integrity of quality control samples is important to both management of overall quality as well as to meeting requirements of proficiency testing.

Thus, the rising adoption of quality control solutions in laboratories and hospitals is expected to drive the market growth.

Opportunities

• Rise in Strategic Acquisition and Partnership among Organizations

Recently, different organizations are stepping forward for partnership and collaboration to develop IVDs that are essential for detecting diseases. Not only can this, with the help of partnerships and agreements, both the companies develop a new suite of technologies and platforms that will help to detect diseases.

With the help of a long-term agreement, both companies can provide dimensional pricing IVDs in response to consumer demand in the market. Such partnership and mutual agreement not only benefit both the companies but are also creating a lot of opportunities for the market to grow.

• Rising Research and Development Activities

Across the globe, the spending on research and development activities is escalating owing to public health expenditure with economic performance. Whereas, the healthcare industry ranks second among all industries when it comes to the amount it spends on research and development. Rising healthcare expenditure has further resulted in better provision of research and development opportunities. Consequently, it has enhanced the demand for IVD regulatory affairs outsourcing services across the region.

Restraints/Challenges

• High Cost Related to Quality Control and Maintenance of IVD

In vitro diagnostics (IVD) are tests done on samples such as blood or tissue that have been taken from the human body. In vitro diagnostics can detect diseases or other conditions, and can be used to monitor a person's overall health to help cure, treat, or prevent diseases.

IVD of analytes originating from body specimens, including blood and tissue biopsies, is used alone or in combination with clinical investigations and is perceived as an important tool for high-quality medical outcomes, hence maintaining of IVD and quality control of IVD devices costs high for carrying out accurate tests.

Hence, the rising cost of the maintenance of IVD has become a deciding factor for the companies in the servicing process, which is further restraining the growth of the market to an extent. 

• Stringent Regulations Regarding IVD in Saudi Arabia, Turkey, and Egypt

The use of IVDs across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases which are preventable by early diagnosis and timely treatments. At the same time, the players of the IVD devices in the market have to follow certain regulations to get approval from the upper authorities for the launching of the product in a region. These stringent guidelines need to be followed, and this is one of the most difficult tasks among all the steps. The pre-market approval of various medical devices varies from one country to another.

Therefore, the stringent rules & regulations for product approval act as restraints for the growth of the market.

Recent Development

• In February 2023, Siemens Healthineers, a leading medical technology company, and Unilabs, a leading diagnostic services provider, announced a multi-year agreement valued at over €200 thousand. Unilabs has invested in Siemens Healthineers top-notch technology and will acquire more than 400 laboratory analyzers to further improve its laboratory infrastructure to offer an unparalleled service to its customers. This partnership has helped for latest diagnostic testing infrastructure to improve patients’ care.
• In July 2021, Thermo Fisher Scientific, the world leader in serving science, announced a collaboration with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers. This has helped the company to increase their global presence in the market.

Saudi Arabia, Turkey, and Egypt in Vitro Diagnostics (IVD) Quality Control Market Scope

Saudi Arabia, Turkey, and Egypt in vitro diagnostics (IVD) quality control market is segmented into four notable segments such as product and services, application, type, sector and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product and Services

• Quality Control Products
• Quality Control Services

On the basis of products and services, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into quality control products and quality control services.

Applications

• Clinical Chemistry
• Immunochemistry
• Hematology
• Molecular Diagnostics
• Coagulation/Hemostasis
• Microbiology
• Others

Based on applications, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into clinical chemistry, immunochemistry, hematology, molecular diagnostics, coagulation/hemostasis, microbiology, and others.

Sector

• Clinical
• Non-Clinical

Based on sector, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into clinical and non-clinical.

End User

• Clinical Laboratories
• Academic And Research Institutes
• Blood Banks
• Biotechnology Industry
• Pharmaceutical Industry
• Others

Based on end users, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into clinical laboratories, academic and research institutes, blood banks, biotechnology industry, pharmaceutical industry, and others.

Competitive Landscape and In Vitro Diagnostics (IVD) Quality Control Market Share Analysis

The in vitro diagnostics (IVD) quality control market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the ataxia market.

Certains des principaux acteurs opérant sur le marché du contrôle qualité des diagnostics in vitro (IVD) sont Bio-Rad Laboratories, Inc, Siemens Healthcare Private Limited, Sysmex Europe SE, Randox Laboratories Ltd., Sera Care, Thermo Fisher Scientific Inc., Beckman Coulter, Inc., Technopath Clinical Diagnostics, DiaSorin SpA, Agappe Diagnostics Ltd et Spectrum Diagnostics. entre autres.

SKU-69908